Skip to content
Medical Health Aged Care

Professor Blossom Stephan joins Dementia Australia as an Honorary Medical Advisor

Dementia Australia 2 mins read

Professor Blossom Stephan has further committed to raising awareness and educating about dementia through her newest role as Dementia Australia Honorary Medical Advisor. 

Dementia Australia CEO Maree McCabe AM officially welcomed Prof Stephan to the position, saying she has made an enormous contribution both to the organisation and, more broadly, to dementia treatment, care and research both in Australia and internationally.  

Blossom was appointed the inaugural Chair of Dementia for Curtin University and Dementia Australia last year to create and drive ambitious research programs in the prevention, detection, and care of dementia across Australia. Blossom is a Professor of Neuroepidemiology and Global Ageing at the University of Nottingham. She leads a program of research on dementia risk prediction and risk reduction in high as well as low and middle-income countries. She was also the Deputy Director of the only National Institute for Health Research Global Health Research Group focused on dementia. 

“We are very fortunate to have had Blossom’s expertise, guidance and support since she became Chair of Dementia last year, and I am delighted that we can continue the relationship in such a significant way,” Ms McCabe said. 

Prof Stephan said she was delighted to continue supporting Dementia Australia in her new capacity as Dementia Australia Honorary Medical Advisor. 

“Dementia has long been a focus of my research and I am looking forward to further contributing to Dementia Australia through the knowledge and expertise I have gained through my work,” Prof Stephan said. 

Prof Stephan will serve alongside Dementia Australia Honorary Medical Advisors Scientia Professor Henry Brodaty AO, Associate Professor Michael Woodward AM and Professor Amy Brodtmann. 

Prof Stephan will also be attending the upcoming Perth Memory Walk & Jog on Sunday 17 March. 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you. 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au  

-Ends- 

Media contacts: Stephen O’Connell, Media & Communications Advisor, Stephen.oconnell@dementia.org.au, 0402 284 257

When talking or writing about dementia please refer to
Dementia-Friendly Language Guidelines. 

Note to Editors:
We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns: 

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.
 
 

Media

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.